The 2022 ICC/WHO classification distinguishes two major subtypes: nodal MCL (80%–90%), usually characterized by unmutated IGHV, SOX11 positivity and aggressive behavior; and non‐nodal leukemic MCL (10%–20%), typically showing mutated IGHV, SOX11 negativity and an indolent course. Here, SOX11 is linked to intrahepatic cholangiocarcinoma.